Management of Severe Aortic Stenosis with HFrEF
Patients with severe aortic stenosis and HFrEF should undergo aortic valve replacement (AVR) regardless of symptom status, while simultaneously initiating and optimizing guideline-directed medical therapy for heart failure.
Immediate Intervention Strategy
Aortic Valve Replacement
Both ESC/EACTS and ACC/AHA guidelines recommend AVR in patients with severe AS and reduced LVEF (typically <50-55%), even when asymptomatic 1, 2. This is a Class I recommendation because:
- Afterload mismatch from severe AS prevents LV recovery despite optimal medical therapy
- Delaying intervention risks irreversible myocardial damage from combined pressure overload and reduced perfusion
- Mortality risk increases substantially when AS and HFrEF coexist 3, 4
Critical distinction: In patients with low-gradient, low-flow AS (small valve area but low gradient due to poor LV function), perform dobutamine stress echocardiography to confirm true severe stenosis versus pseudostenosis before proceeding 4. Only patients with true severe AS benefit from intervention.
Choice of Intervention: TAVR vs SAVR
- TAVR is preferred in most patients with HFrEF due to lower procedural risk and faster recovery 5, 3
- SAVR remains appropriate for younger patients (<65-70 years) or those requiring concomitant coronary revascularization
- Heart Team evaluation is mandatory (Class I recommendation) 1
Concurrent Heart Failure Management
Pharmacological Therapy Sequence
Before AVR (if hemodynamically stable): Start GDMT cautiously, as severe AS limits cardiac output augmentation:
- Diuretics first - for congestion relief, but avoid overdiuresis which worsens low-flow state 6
- Beta-blockers at low dose - if heart rate >70 bpm and blood pressure tolerates (carvedilol, metoprolol succinate, or bisoprolol) 6, 7
- Avoid aggressive afterload reduction - ACE inhibitors/ARBs must be used with extreme caution or deferred until after AVR, as they can precipitate hypotension and hypoperfusion in severe AS
After AVR: Aggressively optimize GDMT within 2-4 weeks post-procedure 8:
- SGLT2 inhibitors - initiate early (dapagliflozin or empagliflozin); minimal BP effect and rapid benefit 7, 8
- Mineralocorticoid receptor antagonists - spironolactone or eplerenone; also minimal BP effect 6, 7
- Sacubitril/valsartan - start at low dose (24/26 mg twice daily) and uptitrate, replacing ACE-I/ARB 6, 8
- Beta-blockers - continue or initiate if not already started, uptitrate to target doses 6, 8
Specific Dosing Strategy for Low Blood Pressure
If systolic BP <100 mmHg but patient has adequate perfusion 7:
- Start SGLT2i and MRA first (no BP effect)
- Add very low-dose sacubitril/valsartan (25 mg twice daily) OR low-dose ACE-I
- If beta-blocker not tolerated, use ivabradine (if sinus rhythm, HR >70 bpm) to facilitate later beta-blocker introduction
- Uptitrate one medication at a time with 1-2 week intervals
Device Therapy Considerations
After AVR and ≥3 months of optimized medical therapy 6:
- ICD if LVEF remains ≤35% and NYHA Class II-III (Class I recommendation for ischemic cardiomyopathy, Class I-B for non-ischemic)
- CRT if LVEF ≤35%, QRS ≥150 msec with LBBB morphology, and NYHA Class II-IV despite optimal therapy 6
Expected Outcomes and Monitoring
LVEF recovery: Approximately 50% of patients show ≥10% improvement in LVEF within 6 months post-AVR 9. Factors predicting recovery include:
- Shorter duration of AS
- Less myocardial fibrosis on cardiac MRI
- Absence of extensive coronary disease
Key monitoring points:
- Echocardiography at 1,6, and 12 months post-AVR to assess LV remodeling
- If LVEF improves to >40%, continue all HFrEF medications indefinitely (termed "HF with improved EF") 8
- If LVEF remains reduced despite AVR and optimal GDMT, consider advanced HF evaluation
Critical Pitfalls to Avoid
- Do not delay AVR to "optimize medical therapy first" - the valve obstruction prevents meaningful improvement 3, 4
- Do not withhold beta-blockers in stable patients post-AVR; they reduce sudden death risk even with low EF 6, 10
- Avoid calcium channel blockers (diltiazem, verapamil) - they worsen HF outcomes (Class III recommendation) 6
- Do not combine ACE-I + ARB + MRA - excessive risk of hyperkalemia and renal dysfunction (Class III) 6
- Recognize that persistent symptoms post-AVR may reflect irreversible myocardial damage, concurrent HFpEF, or other comorbidities requiring separate management 11